Nitric Oxide as an Adjuvant Therapeutic in the Clinical Management of Cancer
- Pp. 191-200 (10)Nicole J. Kenote, Tysha N. Medeiros, Dana M. Jarigese, Melissa A. Edwards and Mark A. Brown
The ability of tumors to develop resistance to cytotoxic therapies has been a major obstacle in the clinical management of cancer. In addition, dose-limiting toxicity represents yet another impediment in the application of traditional therapeutics. To enhance the sensitivity of tumors to radio-therapeutics, researchers are increasingly turning to nitric oxide for its potential as a powerful adjuvant to existing therapies. Here, we review the aptitude of nitric oxide to serve as a radio-sensitizing, adjuvant therapeutic for the clinical management of cancer.